| Breakdown | TTM | Dec 2025 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 251.78M | ― | 251.78M | 331.50M | 294.48M | 327.89M |
| Gross Profit | 181.47M | ― | 181.47M | 242.07M | 193.46M | 219.21M |
| EBITDA | 11.95M | ― | 11.95M | -561.43M | -5.58M | -160.42M |
| Net Income | -18.71M | ― | -18.71M | -588.08M | -56.25M | -310.83M |
Balance Sheet | ||||||
| Total Assets | 630.59M | ― | 630.59M | 702.36M | 1.30B | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 87.45M | ― | 87.45M | 126.99M | 110.36M | 115.16M |
| Total Debt | 217.12M | ― | 217.12M | 295.24M | 289.33M | 286.82M |
| Total Liabilities | 479.92M | ― | 479.92M | 561.26M | 602.72M | 605.54M |
| Stockholders Equity | 150.68M | ― | 150.68M | 141.10M | 694.88M | 712.95M |
Cash Flow | ||||||
| Free Cash Flow | 46.82M | ― | 46.82M | 12.20M | 2.37M | -19.58M |
| Operating Cash Flow | 61.17M | ― | 61.17M | 17.20M | 7.50M | -2.14M |
| Investing Cash Flow | -10.55M | ― | -10.55M | 4.38M | 5.82M | -10.56M |
| Financing Cash Flow | -87.00M | ― | -87.00M | 225.00K | -5.33M | -19.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $459.25M | 54.36 | 3.87% | ― | 4.42% | 165.42% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
56 Neutral | $518.87M | -15.16 | -44.64% | ― | 17.34% | -8.35% | |
55 Neutral | $528.49M | -24.64 | -12.83% | ― | -24.05% | 96.90% | |
50 Neutral | $408.54M | ― | ― | ― | -17.50% | -51.25% | |
48 Neutral | $4.66B | -13.30 | -90.15% | ― | 120.52% | -124.81% |
On December 23, 2025, Cerence entered into privately negotiated transactions with certain holders of its 1.50% Convertible Senior Notes due 2028 to repurchase $30 million in aggregate principal amount at 92% of face value, plus accrued and unpaid interest up to but excluding the settlement date. The company plans to cancel the repurchased notes, reducing its outstanding convertible debt and modestly improving its capital structure ahead of the notes’ 2028 maturity, which may be seen as a proactive balance-sheet management step for debtholders and equity investors.
The most recent analyst rating on (CRNC) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Cerence stock, see the CRNC Stock Forecast page.
Cerence, a company involved in patent disputes with Samsung, resolved its legal battles through a cross-license agreement. This agreement, reached on October 28, 2025, required Samsung to make a one-time payment of $49.5 million to Cerence, concluding a series of lawsuits filed by both parties over patent infringements.
The most recent analyst rating on (CRNC) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Cerence stock, see the CRNC Stock Forecast page.